: Patients in clinical trials were generally younger, with a mean age of 58 compared to 61 in this real-world group.
: Despite the high rate of stopping, the overall survival and progression-free survival (estimated at 35 months) remained excellent. Real-World vs. Clinical Trials (616 KB)
Toxicities and outcomes of 616 ibrutinib-treated patients in ... - PMC : Patients in clinical trials were generally younger,
: Both groups had roughly the same time (about 85–87 months) from their initial diagnosis until they started ibrutinib treatment. Clinical Implications (616 KB)